Company profile
PTC Therapeutics, Inc.
NASDAQ: PTCT · Healthcare · Biotechnology
#121 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
72BFH 65DQ 80GM 73SS 79
v0.1 · 65/100 weight · provisional
↑ operating margin, net margin · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$827.1M
Rev growth YoY (TTM)
-53.3%
Net income (FY)
$682.6M
Employees
991
as of 2026-08-06
Market cap
$5.8B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.7B$1.7B2025
Net income$682.6M$682.6M2025
Operating income$866.9M$866.9M2025
Total assets$2.9B$2.9B2025
Liabilities$3.1B$3.1B2025
Equity-$205.3M-$205.3M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration and License Revenue55%
Product32%
Royalty13%
By geography
Non-US57%
UNITED STATES43%
The read
What is PTC Therapeutics, Inc.’s revenue?
PTC Therapeutics, Inc. booked $1.7B in FY2025 revenue, growing 115% year over year — faster than most Healthcare companies we track, at a 39.4% net margin.
Peers · Healthcare
Integer Holdings Corporation84B+Healthcare Services Group, Inc.87AAmerican Oncology Network, Inc.——Integra LifeSciences Holdings Corporation67BLantheus Holdings, Inc.79B+Merit Medical Systems, Inc.83B+Neighbors
Warren →Key facts
CEOMatthew Klein
SectorHealthcare
IndustryBiotechnology
HeadquartersWarren, NJ
ExchangeNASDAQ: PTCT
Employees991
IPO date2013-06-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.